JP2009096768A - Ligament cell activator - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a ligament cell activator activating a weakened ligament cell and applicable to the field of beautification and medical treatment. <P>SOLUTION: The ligament cell activator comprises one or more kinds selected from among an extract from Rosa centifolia Linne (Rosaceae), and an extract from Artemisia princeps Pampanini. An external preparation for skin for activating the ligament cell is prepared by formulating the ligament cell activator. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

  The present invention relates to a ligament cell activator, and particularly to a ligament cell activator that activates a weakened ligament cell and improves the state of the ligament, a ligament cell-utilizing skin external preparation using the same, and a ligament cell activation method. is there.

Conventionally, research on aging changes in facial morphology has been advanced. There are muscles on the face that move the skin called facial muscles and are involved in the creation of facial expressions, but as these muscles weaken with age and frequency of use, facial expressions become poor and sagging facial skin It is thought to occur. Facial skin sagging is one of the major cosmetic problems, and conventionally, various beauty treatments such as massage and exercises to train facial expression muscles have been performed. It has been found that it has an action of activating muscle cells of muscles, and a drug that prevents and improves facial sagging using this has been developed (see Patent Document 1).
On the other hand, the ligament is a fibrous structure that supports the facial morphology, but when the ligament loosens, facial sagging occurs. Therefore, when ligament surgery was performed, there was a report that sagging was improved (Non-patent Document 1).

JP 2007-230965 A Plastic And Reconstructive Surgery, 110, 1134

  The present invention has been made in response to the conventional circumstances as described above, and can activate a ligament without surgery, and can activate this in the field of beauty or medicine. The purpose is to provide an agent.

  As a result of intensive studies aimed at solving the above problems, the present inventor has found that a specific plant extract exhibits excellent ligament cell activation activity, and has completed the present invention.

  The present invention is a ligament cell activator comprising at least one selected from rose rose extract and mugwort extract.

  Moreover, this invention is a ligament cell utilization skin external preparation characterized by including 1 or more types chosen from the rose rose extract and the Artemisia extract.

The ligament cell activator of the present invention can be applied to the field of beauty by activating a weakened ligament and pulling up facial muscles whose supporting ability has decreased due to aging or the like. In addition, by activating ligament cells, it is possible to improve diseases such as injury and uterine prolapse accompanied by ligament damage.
The ligament cell-use skin external preparation of the present invention can be activated by external application without surgery of the ligament by blending the above-mentioned ligament cell activator into the base for external use, and is used for beauty, medical treatment, etc. be able to.

The best mode of the present invention will be described below.
The ligament cell activator of the present invention contains one or more selected from rose rose extract and mugwort extract.
The rose is a member of the genus Rosaceae, and its scientific name is Rosa centifolia Linne (Rosaceae). The rose extract is known to have a fibrinolytic activity inhibiting action and a whitening action (JP 2000-327555 A, JP 2002-29959 A), but it has a ligament activation effect. Has never been known. In addition, JP 2002-241299 A, JP 2004-359632 A, JP 2005-206568 A, JP 2006-241148 A, and JP 2007-186457 A describe a plant extraction of the family Rosaceae. There is a description of wrinkle and sagging improvement by material, but there is no description of ligament.

  Furthermore, Artemisia princeps Pampanini, Artemisia mongolia, Artemisia montata Pampanini are included in Artemisia princeps Pampanini. Artemisia extract is known to have antiseptic action, bactericidal action, blood circulation promoting action, and capillary permeability inhibiting action, but it has not been known at all that it has a ligament activation action.

  The plant extract used in the present invention is obtained by immersing or heating and refluxing the above-mentioned plant leaves, stems including roots, roots, flowers, whole plants, etc. together with an extraction solvent, followed by filtration and concentration. The extraction solvent used in the present invention may be any solvent as long as it is usually used for extraction, and in particular, alcohols such as methanol, ethanol, 1,3-butylene glycol and propylene glycol, hydrous alcohols, water, acetone and ethyl acetate. Although organic solvents such as esters can be used alone or in combination, water, alcohols and hydrous alcohols are particularly preferred. The ligament cell activator of the present invention comprises the above plant extract, but may be a plant extract using the above plant alone or a plant extract using a mixture.

As a preferable extraction site of each plant, the rose is a flower and the mugwort is a leaf. However, each plant can also use extracts from other parts such as leaves, flowers, stems, roots and fruits.
These plants may be native or cultivated plants.
Commercially available rose extract and mugwort extract can be used. For example, rose extract BG (manufactured by Maruzen Pharmaceutical Co., Ltd.) can be cited as the rose extract.

  In addition, although the ligament cell activator of the present invention is a blended raw material substantially consisting of one or more of the above plant extracts, it may contain other components. This ligament cell activator is blended in the base and applied in the form of a poultice, an iontophoretic agent, an external preparation and the like.

  The blending amount of the above plant extract in the ligament cell-utilizing skin external preparation of the present invention is preferably from 0.0005 to 1% by mass, more preferably from 0.001 to 0.01% in terms of dry matter of rose rose extract and mugwort extract. % By mass.

  The ligament cell-stimulating skin external preparation of the present invention is produced by blending the ligament cell activator according to the present invention with the base of the skin external preparation. The ligament cell-utilizing skin external preparation of the present invention is a component usually used in skin external preparations such as cosmetics and pharmaceuticals, for example, whitening agents, moisturizers, antioxidants, oily components, ultraviolet absorbers, surfactants, A viscosity agent, alcohols, powder components, color materials, aqueous components, water, various skin nutrients, various drugs, chelating agents, pH adjusters, and the like can be appropriately blended as necessary.

  The ligament cell-utilizing skin external preparation of the present invention means a composition applied to the skin in the fields of pharmaceuticals, quasi drugs, cosmetics and the like. The dosage form is not limited as long as the effect of the present invention is exhibited. Any ointment, cream, milky lotion, lotion, pack, bath preparation, etc. may be used as long as it is a product conventionally used for an external preparation for skin.

  The ligament cell activation method of the present invention is realized by a method of absorbing one or more selected from rose rose extract and mugwort extract from the skin in the form of a poultice, iontophoretic agent, external preparation and the like.

The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto. Unless otherwise specified, the amount is shown in mass%.
First, the test method regarding the ligament cell activation effect of this invention and its result are demonstrated.

A. Preparation of plant extract The following experiment was performed using a rose extract BG (manufactured by Maruzen Seiyaku Co., Ltd.) for the rose extract and a mugwort extract extracted with water using a conventional method.

B. Method for measuring ligament cell activation effect and results (1) Method for measuring ligament cell activation effect The measurement of the ligament cell activation effect was performed using the respiratory activity promoting effect of ligament cells as an index.
Ligament cells were seeded in a 24-well plate and replaced with low serum medium after 6 hours. After 12 hours, a drug diluted to a predetermined concentration and alamablue were added, and after 3 hours, the fluorescence intensity was measured (excitation light: 550 nm, measurement light: 590 nm). The fluorescence intensity when no drug was added was set to 100%, and the ligament cell activation effect was evaluated by the relative value (% of control).

(2) Measurement result of ligament cell activation effect Fluorescence intensity when adding rose rose extract BG to 0.0005 mass%, 0.001 mass%, 0.002 mass% (in terms of dry matter) The result (% of control) expressed as a relative value with respect to the fluorescence intensity at the time of addition is shown in FIG. FIG. 1 shows that the rose extract has a significant ligament cell activation effect at 0.0005 mass%.
Moreover, the result of having measured the relative intensity | strength of the fluorescence when adding a mugwort extract so that it may become 0.001 mass% (dry matter conversion) is shown in FIG. FIG. 2 shows that the mugwort extract has a significant ligament cell activation effect at 0.001% by mass.
Therefore, it turns out that these extracts are effective as a ligament cell activator.

FIG. 3 shows the results of a test similar to that described above for the rose extract and other rose family plants (Novara, Tonin) in the same manner as described above. In addition, 0.001 mass% (dry matter conversion) was used for each plant extract.
It can be seen from FIG. 3 that no rosehip extract or tonin extract other than the rose extract has a ligament cell activation effect.

  Examples using the ligament cell activator according to the present invention in various dosage forms are shown below, but the present invention is not limited by these formulation examples, and is specified by the claims. Needless to say.

Example 1 (oil-based foundation)
Compounding ingredients Compounding amount (% by mass)
Fine particle titanium oxide 10.0
Mica 22.4
Kaolin 10.0
Nylon powder 5.0
Red iron oxide 0.5
Yellow iron oxide 0.5
Black iron oxide 0.1
Liquid paraffin remaining dimethylpolysiloxane 10.0
Sorbitan sesquioleate 2.0
Octyl methoxycinnamate 5.0
Rose rose extract 0.001 (dry residue)
Perfume Appropriate amount Microcrystalline wax 6.0
Carnauba Arrow 3.0

(Production method)
Fine particles of titanium oxide, mica, kaolin, nylon powder, red iron oxide, yellow iron oxide and black iron oxide were thoroughly mixed and ground in a blender (powder part). Components other than the fragrance were mixed and heated and melted at 85 ° C. (oil phase). The powder was added to this oil phase with stirring. Next, a fragrance was added and thoroughly ground and dispersed, and then filled into a container and molded to obtain an oily foundation.

Example 2 (milky lotion)
Compounding ingredients Compounding amount (% by mass)
Stearic acid 6.0
Sorbitan monostearate ester 2.0
Polyoxyethylene (20 mol) sorbitan monostearate 1.5
2- (2′-Hydroxy-5′-methylphenyl) benzotriazole 8.0
Propylene glycol 10.0
Rose rose extract 0.001 (dry residue)
Artemisia extract 0.001 (dry residue)
Antiseptic / Antioxidant Appropriate amount of perfume Appropriate amount of purified water

(Production method)
Propylene glycol was added to purified water and heated to maintain 70 ° C. (aqueous phase). On the other hand, other components were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase with stirring to perform preliminary emulsification. Next, the emulsified particles of the system were made fine and uniform with a homomixer, and then rapidly cooled with good stirring to obtain an emulsion.

Example 3 (cream)
Compounding ingredients Compounding amount (% by mass)
Polyoxyethylene (20 mol) cetyl alcohol ether 1.0
Methylphenyl polysiloxane (20cs) 2.0
Liquid paraffin 3.0
2-Hydroxy-4-methoxybenzophenone 5.0
Rose rose extract 0.002 (dry residue)
Propylene glycol 5.0
Glycerin 2.0
Ethyl alcohol 15.0
Carboxyvinyl polymer 0.3
Hydroxypropyl cellulose 0.1
2-Aminomethylpropanol 0.1
Preservative Appropriate amount of perfume Appropriate amount

(Production method)
Propylene glycol was added to purified water and heated to maintain 70 ° C. (aqueous phase). On the other hand, other components were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase with stirring to perform preliminary emulsification. Next, the emulsified particles of the system were made fine and uniform with a homomixer, and then rapidly cooled with good stirring to obtain a cream.

Example 4 (ointment)
Compounding ingredients Compounding amount (% by mass)
Rose rose extract 1 (dry residue)
Retinol palmitate 0.5
Stearyl alcohol 18.0
Owl 20.0
Polyoxyethylene (20) monooleate 0.25
Glycerin monostearate 0.3
Vaseline 40.0
Purified water residue

(Production method)
The rose extract is added to purified water and dissolved, and kept at 70 ° C. (aqueous phase). The remaining components are mixed and dissolved at 70 ° C. (oil phase). An oil phase was added to the aqueous phase, and the mixture was uniformly emulsified with a homomixer and then cooled to obtain an ointment.

Example 5 (Patch)
Compounding ingredients Compounding amount (% by mass)
(1) Rose rose extract 0.001 (dry residue)
(2) Crotamiton 3.2
(3) Panacet 875R 2.5
(4) Squalane 1.0
(5) dl-Camphor 0.07
(6) Polyoxyethylene (60 mol) hydrogenated castor oil 1.2
(7) Concentrated glycerin 5.0
(8) Gelatin 1.2
(9) Polyvinylpyrrolidone K-90 0.6
(10) Methylparaben appropriate amount (11) d-sorbitol solution 35.0
(12) Aluminum hydroxide 0.2
(13) Urea 1.3
(14) Sodium sulfite appropriate amount (15) Sodium edetate appropriate amount (16) Citric acid appropriate amount (17) Hibiswako 104R 0.22
(18) Sodium polyacrylate 0.24
(19) Sodium carboxymethylcellulose 2.8
(20) Kaolin 1.0
(21) Purified water remaining

Example 6 (Iontophoretic agent)
Compounding ingredients Compounding amount (% by mass)
Rose rose extract 0.002 (dry residue)
Glycerin 5.0
1,3-butylene glycol 5.0
Hyaluronic acid 0.05
Citric acid (food) 0.35
Ion exchange water 87.6

It is a figure which shows the result of having measured the relative intensity | strength of the fluorescence when changing a density | concentration about a rose extract. It is a figure which shows the result of having measured the relative intensity | strength of a 0.001% dry residue and the fluorescence of control about a mugwort extract. It is a figure which shows the result of having measured the relative intensity | strength of the fluorescence when using a rose rose extract and another rose family plant.

Claims (2)

  A ligament cell activator comprising at least one selected from rose rose extract and mugwort extract.   An external preparation for skin application utilizing ligament cells, comprising at least one selected from rose extract and mugwort extract.

Images